Video games are adapted into films all the time. Though most don't turn out to be so great, one success story is Resident Evil. Even if the film's aren't spectacular and don't really have all that much to do with the plot of the survival horror game series on which they are based, they have proven to be popular enough to receive sequel after sequel.

Perhaps it is the film franchise's success that gave Capcom the courage to make a Resident Evil play. Yes, this is apparently an actual thing that will be happening, and it's coming next month.

Via Anime News Network, the play will be an all new story revolving around a "bioterrorism" incident that occurs at an Australian university. Longtime Resident Evil character Chris Redfield, along with his partner Piers Nivans, arrive on the scene to investigate the act of terror, working together with former S.T.A.R.S. member Rebecca chambers, who happens to be teaching at the university. A number of new characters will introduced as well in the form of various students, police officers and the president of the university.

It was announced today that singer Asuka Kuramochi will be joining the play as its lead heroine, a student at the university who is described as having an IQ of 230.

It's hard to imagine how all of this might play out. Resident Evil has always been filled with melodrama, but recently the series has taken more of a Michael Bay-style action approach. Perhaps the play will take inspiration from the original game in the series, which had the S.T.A.R.S. special forces team investigating the creepy, zombie filled Spencer Mansion. The play will supposedly use "darkness" and video in order to establish a creepy mood that will "provide a more personal experience for the audience."

Biohazard the Stage (Biohazard is the Japanese title for Resident Evil) will premiere at Tokyo's EX Theater Roppongi on Oct. 22 and run through Nov. 1. Tickets will cost 8,900 yen, or about $74 US dollars.

Be sure to follow T-Lounge on Twitter and visit our Facebook page 

ⓒ 2024 TECHTIMES.com All rights reserved. Do not reproduce without permission.
Join the Discussion